Akiko Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akiko Ishii has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Akira Tamaoka
Neurology, University of Tsukuba, Tsukuba, Ibaraki, Japan
7 shared publications- Akira Tamaoka
Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennoudai, Tsukuba, Ibaraki 305-8575, Japan
4 shared publications Hiroshi Tsuji
Neurology, University of Tsukuba, Tsukuba, Ibaraki, Japan
3 shared publications- Kiyotaka Nakamagoe
Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
3 shared publications Yasushi Tomidokoro
Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
3 shared publicationsHironori Okada
Department of Molecular Therapy, National Institute of Neuroscience, NCNP, Tokyo, Japan
2 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5)
LRP12 CGG Repeat Expansions in Patients With Adult-Onset Non-5q Spinal Muscular Atrophy
- 1 October 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5)
LRP12 CGG Repeat Expansions in Patients With Adult-Onset Non-5q Spinal Muscular Atrophy
- Open Access
- 21 June 2023
- Published by BMJ in BMJ Neurology Open
- Vol. 5 (1) , e000428
Characteristics of hypersomnia due to inflammatory demyelinating diseases of the central nervous system
Background Neuromyelitis optica spectrum disorder (NMOSD) diagnostic criteria for inflammatory demyelinating central nervous system diseases included symptomatic narcolepsy; however, no relevant case‐control studies exist. We aimed to examine the relationship among cerebrospinal fluid orexin‐A (CSF‐OX) levels, cataplexy and diencephalic syndrome; determine risk factors for low-and-intermediate CSF‐OX levels (≤200 pg/mL) and quantify hypothalamic intensity using MRI. Methods This ancillary retrospective case‐control study included 50 patients with hypersomnia and 68 controls (among 3000 patients) from Akita University, the University of Tsukuba and community hospitals (200 facilities). Outcomes were CSF‐OX level and MRI hypothalamus‐to‐caudate‐nucleus‐intensity ratio. Risk factors were age, sex, hypersomnolence and MRI hypothalamus‐to‐caudate‐nucleus‐intensity ratio >130%. Logistic regression was performed for the association between the risk factors and CSF‐OX levels ≤200 pg/mL. Results The hypersomnia group (n=50) had significantly more cases of NMOSD (p130% had a higher rate of diencephalic syndrome (pConclusions Considering orexin as reflected by CSF‐OX levels and MRI hypothalamus‐to‐caudate‐nucleus‐intensity ratio may help diagnose hypersomnia with diencephalic syndrome.
- 21 June 2023
- Published by BMJ in BMJ Neurology Open
- Vol. 5 (1) , e000428
Open AccessCharacteristics of hypersomnia due to inflammatory demyelinating diseases of the central nervous system
Background Neuromyelitis optica spectrum disorder (NMOSD) diagnostic criteria for inflammatory demyelinating central nervous system diseases included symptomatic narcolepsy; however, no relevant case‐control studies exist. We aimed to examine the relationship among cerebrospinal fluid orexin‐A (CSF‐OX) levels, cataplexy and diencephalic syndrome; determine risk factors for low-and-intermediate CSF‐OX levels (≤200 pg/mL) and quantify hypothalamic intensity using MRI. Methods This ancillary retrospective case‐control study included 50 patients with hypersomnia and 68 controls (among 3000 patients) from Akita University, the University of Tsukuba and community hospitals (200 facilities). Outcomes were CSF‐OX level and MRI hypothalamus‐to‐caudate‐nucleus‐intensity ratio. Risk factors were age, sex, hypersomnolence and MRI hypothalamus‐to‐caudate‐nucleus‐intensity ratio >130%. Logistic regression was performed for the association between the risk factors and CSF‐OX levels ≤200 pg/mL. Results The hypersomnia group (n=50) had significantly more cases of NMOSD (p130% had a higher rate of diencephalic syndrome (pConclusions Considering orexin as reflected by CSF‐OX levels and MRI hypothalamus‐to‐caudate‐nucleus‐intensity ratio may help diagnose hypersomnia with diencephalic syndrome.
- 3 May 2023
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 94 (10) , 876-878
Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis
Excitotoxicity or dysregulation of glutamatergic signalling has long been considered a plausible mechanism underlying motor neuron death in both sporadic and familial ALS.1 In healthy neurons, the glutamine/arginine (Q/R) site of all expressed GluA2, a subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, is subjected to RNA editing by adenosine deaminase acting on RNA 2 (ADAR2), which catalyses adenosine-to-inosine conversion of premessenger RNA.1 In the lower motor neurons of patients with sporadic ALS, Q/R site-unedited GluA2 mRNA is expressed due to ADAR2 downregulation,2 resulting in AMPA receptor-mediated death of motor neurons.1 Transactive response DNA-binding protein of 43 kDa (TDP-43) pathology, the pathological hallmark of ALS, invariably colocalises with ADAR2 deficiency in the spinal motor neurons of patients with sporadic ALS.3 Therefore, Q/R site-unedited GluA2 expression due to ADAR2 downregulation is involved in sporadic ALS pathogenesis.
- 3 May 2023
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 94 (10) , 876-878
Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis
Excitotoxicity or dysregulation of glutamatergic signalling has long been considered a plausible mechanism underlying motor neuron death in both sporadic and familial ALS.1 In healthy neurons, the glutamine/arginine (Q/R) site of all expressed GluA2, a subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, is subjected to RNA editing by adenosine deaminase acting on RNA 2 (ADAR2), which catalyses adenosine-to-inosine conversion of premessenger RNA.1 In the lower motor neurons of patients with sporadic ALS, Q/R site-unedited GluA2 mRNA is expressed due to ADAR2 downregulation,2 resulting in AMPA receptor-mediated death of motor neurons.1 Transactive response DNA-binding protein of 43 kDa (TDP-43) pathology, the pathological hallmark of ALS, invariably colocalises with ADAR2 deficiency in the spinal motor neurons of patients with sporadic ALS.3 Therefore, Q/R site-unedited GluA2 expression due to ADAR2 downregulation is involved in sporadic ALS pathogenesis.
- Open Access
- 1 January 2023
- Published by Japan Society of Kansei Engineering in International Symposium on Affective Science and Engineering
- Vol. ISASE2023, 1-4
Development of a Cognitive Training System Based on Decoding of Single-Trial Event-Related Potentials
Our final goal is to promote brain health by developing a brain-machine interface (BMI)-based cognitive training device. We have been developing a cognitive level assessment device called the "Neurotrainer," which uses event-related potential (ERP) analysis. This device was operated by decoding single-trial ERPs using pattern recognition. Here, we extended our method to decoding single-trial ERPs during a racing game with 8 choices of characters. The decoding accuracy of the target character was about 54% for a single trial and 83% for a cumulative total of five trials (chance level = 12.5%). Also, the ERP responses were stronger in the feedback condition than in the no-feedback condition. These results suggest that the BMI might be an effective tool for cognitive training, in which real-time neurofeedback affects the activation of the brain of the players.
- 1 January 2023
- Published by Japan Society of Kansei Engineering in International Symposium on Affective Science and Engineering
- Vol. ISASE2023, 1-4
Open AccessDevelopment of a Cognitive Training System Based on Decoding of Single-Trial Event-Related Potentials
Our final goal is to promote brain health by developing a brain-machine interface (BMI)-based cognitive training device. We have been developing a cognitive level assessment device called the "Neurotrainer," which uses event-related potential (ERP) analysis. This device was operated by decoding single-trial ERPs using pattern recognition. Here, we extended our method to decoding single-trial ERPs during a racing game with 8 choices of characters. The decoding accuracy of the target character was about 54% for a single trial and 83% for a cumulative total of five trials (chance level = 12.5%). Also, the ERP responses were stronger in the feedback condition than in the no-feedback condition. These results suggest that the BMI might be an effective tool for cognitive training, in which real-time neurofeedback affects the activation of the brain of the players.
- Open Access
- 25 June 2022
- Published by Springer Nature in BMC Research Notes
- Vol. 15 (1) , 1-5
Reduced CSF orexin levels in rats and patients with systemic inflammation: a preliminary study
Objective: Sepsis is a lethal condition characterized by systemic inflammation and multiple organ failure; this condition was initially defined as systemic inflammatory response syndrome (SIRS) due to infection. We previously reported that the hypothalamic neuropeptide orexin improved survival in a murine model of sepsis by mainly acting in the medullary raphe nucleus through orexin type-2 receptors. We hypothesized that orexin treatment enhances recovery from sepsis by reversing the reduction in orexin levels in the cerebrospinal fluid (CSF). We recently reported a case in which CSF orexin levels were reduced in a patient with sepsis. Herein, we attempted to further investigate CSF orexin levels in rats and patients with systemic inflammation. This patient study was a single-center, retrospective observational study. Results: CSF orexin levels were low in rats with lipopolysaccharide-induced systemic inflammation. We enrolled 14 patients with meningitis/encephalitis. Six patients were diagnosed with SIRS, of whom 5 patients had infections (“sepsis” by the previous definition). CSF orexin levels were low in SIRS patients. The results support the hypothesis that orexin treatment enhances recovery from sepsis by reversing the reduction in CSF orexin levels.
- 25 June 2022
- Published by Springer Nature in BMC Research Notes
- Vol. 15 (1) , 1-5
Open AccessReduced CSF orexin levels in rats and patients with systemic inflammation: a preliminary study
Objective: Sepsis is a lethal condition characterized by systemic inflammation and multiple organ failure; this condition was initially defined as systemic inflammatory response syndrome (SIRS) due to infection. We previously reported that the hypothalamic neuropeptide orexin improved survival in a murine model of sepsis by mainly acting in the medullary raphe nucleus through orexin type-2 receptors. We hypothesized that orexin treatment enhances recovery from sepsis by reversing the reduction in orexin levels in the cerebrospinal fluid (CSF). We recently reported a case in which CSF orexin levels were reduced in a patient with sepsis. Herein, we attempted to further investigate CSF orexin levels in rats and patients with systemic inflammation. This patient study was a single-center, retrospective observational study. Results: CSF orexin levels were low in rats with lipopolysaccharide-induced systemic inflammation. We enrolled 14 patients with meningitis/encephalitis. Six patients were diagnosed with SIRS, of whom 5 patients had infections (“sepsis” by the previous definition). CSF orexin levels were low in SIRS patients. The results support the hypothesis that orexin treatment enhances recovery from sepsis by reversing the reduction in CSF orexin levels.
- 30 November 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (11) , e237250
Amyopathic dermatomyositis combined with peripheral neuropathy
We provide the first report of amyopathic dermatomyositis combined with peripheral neuropathy. Our patient, a 49-year-old woman, initially experienced muscle weakness and tingling sensations in her legs, and nerve conduction study findings and the detection of antiganglioside antibodies indicated that she had autoimmune peripheral neuropathy. The unexpected presence of skin lesions, interstitial pneumonia and antibodies to melanoma differentiation-associated protein 5 prompted an additional diagnosis of amyopathic dermatomyositis. No previous report has described amyopathic dermatomyositis with peripheral neuropathy, and the present case provides evidence for the once-controversial concept of neuromyositis.
- 30 November 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (11) , e237250
Amyopathic dermatomyositis combined with peripheral neuropathy
We provide the first report of amyopathic dermatomyositis combined with peripheral neuropathy. Our patient, a 49-year-old woman, initially experienced muscle weakness and tingling sensations in her legs, and nerve conduction study findings and the detection of antiganglioside antibodies indicated that she had autoimmune peripheral neuropathy. The unexpected presence of skin lesions, interstitial pneumonia and antibodies to melanoma differentiation-associated protein 5 prompted an additional diagnosis of amyopathic dermatomyositis. No previous report has described amyopathic dermatomyositis with peripheral neuropathy, and the present case provides evidence for the once-controversial concept of neuromyositis.
- Open Access
- 1 September 2020
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 18, 44-49
rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
- 1 September 2020
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 18, 44-49
Open AccessrAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
- Open Access
- 1 June 2020
- Published by Elsevier in eNeurologicalSci
- Vol. 19, 100236
Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
- 1 June 2020
- Published by Elsevier in eNeurologicalSci
- Vol. 19, 100236
Open AccessPembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
- 1 February 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 409, 116579
Radiological findings in siblings with dysferlin mutation with diverse phenotype
- 1 February 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 409, 116579
Radiological findings in siblings with dysferlin mutation with diverse phenotype
- 1 October 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 405, 116429
GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis
- 1 October 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 405, 116429
GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis